On December 7, TINAVI announced that it plans to jointly increase its capital to the Jishuitan Orthopedic Robot Engineering Research Center with Beijing Shuimu Oriental Medical Robot Technology Innovation Center (hereinafter referred to as "Shuimu Oriental") and Beijing Jishuitan Hospital affiliated to Capital Medical University to promote the clinical research and popularization of orthopedic robotic surgery.
In this capital increase, TINAVI contributed 7.4 million yuan in cash, Shuimu Oriental contributed 2.4 million yuan in cash, and Beijing Jishuitan Hospital contributed 10.2 million yuan in assets, and authorized Beijing Jishuitan Xinxing Medical Technology Co., Ltd. (hereinafter referred to as "Xinxing Medical") to hold and manage the corresponding equity.
Beijing Jishuitan Hospital was approved as the Beijing Key Laboratory of Orthopedic Robotics Technology in 2016, and during the "14th Five-Year Plan" period, it was successively approved as the Beijing Engineering Research Center for Orthopedic Surgical Robots, the Beijing Research Ward Demonstration Construction Unit, and was selected as the first batch of project reserves of the National Emergency Medical Rescue Base, becoming the output hospital of the national regional medical center construction project, and approved as the National Orthopedic Medical Center in 2022. The Jishuitan Orthopedic Robot Engineering Research Center, which the three parties plan to increase their capital this time, was established in December 2021 and is jointly established by the above three parties, which is the supporting unit of the "Beijing Engineering Center for Orthopedic Surgical Robots", and the implementation unit of the 5G + Orthopedic Robot Alliance of the National Orthopedic Medical Center. Prior to the capital increase, Sunrise Medical held 51% of the shares, TINAVI held 25% of the shares, and Shuimu Oriental held 24% of the shares. After the capital increase, the shareholding ratio of Xinxing Medical remained unchanged, TINAVI's shareholding ratio increased to 33%, and Mizuki Dongfang's shareholding ratio became 16%.
Proofreading by Yang Xuli.